France (FR)

ICDAR 2021 Competition on Historical Document Classification (2021) Seuret M, Nicolaou A, Rodríguez-Salas D, Weichselbaumer N, Stutzmann D, Mayr M, Maier A, Christlein V Conference contribution, Conference Contribution The contribution of insects to global forest deadwood decomposition (2021) Seibold S, Rammer W, Hothorn T, Seidl R, Ulyshen MD, Lorz J, Cadotte MW, et al. Journal article A mathematical model to estimate the number of unreported SARS-CoV-2 infections in the early phase of the pandemic using Germany and Italy as examples Ein mathematisches Modell zur Schätzung der Dunkelziffer von SARS-CoV-2-Infektionen in der Frühphase der Pandemie am Beispiel Deutschland und Italien (2021) Fiedler J, Moritz CP, Feth S, Speckert M, Dressler K, Schoebel A Journal article Topological magnon insulators in two-dimensional van der Waals ferromagnets CrSiTe3 and CrGeTe3: Toward intrinsic gap-tunability (2021) Zhu F, Zhang L, Wang X, Dos Santos FJ, Song J, Mueller T, Schmalzl K, et al. Journal article Multispectral optoacoustic tomography of lipid and hemoglobin contrast in human carotid atherosclerosis (2021) Karlas A, Kallmayer M, Bariotakis M, Fasoula NA, Liapis E, Hyafil F, Pelisek J, et al. Journal article An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST) (2021) Ahrens M, Escudier B, Haanen JBAG, Boleti E, Goupil GM, Grimm MO, Negrier S, et al. Conference contribution The CAR-HEMATOTOX model identifies patients with a high risk for CAR T-cell related hematotoxicity and is associated with prolonged hospitalization and poor prognosis (2021) Rejeski K, Perez A, Sesques P, Berger C, Jentzsch L, Mougiakakos D, Froelich L, et al. Conference contribution Clinical phenotypes of CAR-T-cell related hematotoxicity in relapsed/refractory large B-cell lymphoma (2021) Rejeski K, Sesques P, Berger C, Jentzsch L, Mougiakakos D, Froelich L, Bucklein , et al. Conference contribution Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study (2021) D'Agostino MA, Schett G, Gaillez C, Guerrero C, Hanova P, Cazenave T, Stoenoiu MS, et al. Conference contribution Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study (2021) Kaeley G, Schett G, Conaghan P, Mcgonagle D, Behrens F, Goupille P, Gaillez C, et al. Conference contribution